Company profile: Galectin Therapeutics
1.1 - Company Overview
Company description
- Provider of galectin-targeted therapeutics and research support, including belapectin (GR-MD-02) in clinical trials for NASH cirrhosis, cancer immunotherapy, and other fibrotic diseases; the NAVIGATE Phase 2b/3 study to prevent esophageal varices in NASH cirrhosis; combination trials with KEYTRUDA; discovery programs for small-molecule and carbohydrate galectin inhibitors; and galectin-3 inhibitor resources for preclinical studies.
Products and services
- Belapectin (GR-MD-02): A polysaccharide-based galactoarabino-rhamnogalacturonan polymer binding galectin-1 and galectin-3, investigated for NASH cirrhosis, cancer immunotherapy applications, and other fibrotic disease indications
- Cancer Immunotherapy: Combination-based clinical studies exploring belapectin with immunotherapy agents such as KEYTRUDA for treating advanced melanoma and head and neck cancer
- NAVIGATE Study: A Phase 2b/3 clinical investigation of belapectin assessing its efficacy in preventing esophageal varices in patients diagnosed with NASH cirrhosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Galectin Therapeutics
Paloma Pharmaceuticals
HQ: United States
Website
- Description: Provider of early-stage drug development focusing on pathologies showing an aberrant up-regulation of the PI3K/Akt/mTOR pathway, including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (renal and pulmonary fibrosis), and CNS (epilepsy and neurodegenerative).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paloma Pharmaceuticals company profile →
KAI Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics through drug discovery and development, with multiple clinical-stage programs in cardiovascular disease, kidney disease, and pain; lead candidate KAI-9803 is in Phase 2b (PROTECTION AMI) evaluating reduction of myocardial injury in heart attack.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KAI Pharmaceuticals company profile →
4P Therapeutics
HQ: United States
Website
- Description: Provider of research and development of novel drug delivery technologies and therapeutics, developing pharmaceutical products from pre-clinical testing to clinical manufacturing, with a focus on meeting the needs of patients, physicians and payers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P Therapeutics company profile →
Meda Pharma
HQ: United States
Website
- Description: Provider of pharmaceutical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Meda Pharma company profile →
Palatin Technologies
HQ: United States
Website
- Description: Provider of targeted receptor-specific peptide therapeutics, including Vyleesi (bremelanotide injection) for premenopausal women with HSDD, and a pipeline of melanocortin-based candidates: PL9643 (Phase 3) for dry eye disease; PL9654 for ocular diseases (IVT and topical); PL8177 (oral, Phase 2) for ulcerative colitis; bremelanotide + PDE5i (Phase 2) for sexual dysfunction; and a planned MCR4 agonist program for obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palatin Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Galectin Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Galectin Therapeutics
2.2 - Growth funds investing in similar companies to Galectin Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Galectin Therapeutics
4.2 - Public trading comparable groups for Galectin Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →